Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund

Executive Summary

Harvard Pilgrim Chief Medical Officer Michael Sherman said the full warranty behind the agreement is the right kind of deal to balance access and cost.

You may also be interested in...



Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal

Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals.

Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season

The latest drug development news and highlights from our US FDA Performance Tracker.

The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics

Using a higher event rate typical of real-world, high-risk CV patients, Amgen asserts Repatha is cost effective at $9,669, the going discounted rate in the market. But criticism over the PCSK9 inhibitors' cost-effectiveness continues.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS120561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel